Zhihao Lu

8PUBLICATIONS
24CO-AUTHORS
Molecular targetsImmunogenetics (incl. genetic immunology)Social epidemiologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 04, 2026
Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

|Sep 11, 2025
Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".

Zhihao Lu, Wenting Du, Xi Jiao

|Jul 10, 2025
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial.

Chang Liu, Dan Liu, Yinghua Ji

|Apr 03, 2025
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

Zhihao Lu, Wenting Du, Xi Jiao

|Jan 14, 2025
Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial.

Lili Song, Ying Pang, Yi He

|Jun 27, 2024
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.

Yanni Wang, Chang Liu, Huan Chen

Pageof 2

Frequent Collaborators

4 joint publications

Lin Shen

3 joint publications

Xiaotian Zhang

3 joint publications

Lin Shen

2 joint publications

Jian Li